NCT04827953View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Gemcitabine

Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).

DRUG

Nab paclitaxel

Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).

DRUG

NLM-001

NLM-001 will be administered three cycles consecutively followed by two rest cycles.

DRUG

Zalifrelimab

Zalifrelimab administration each 6 weeks.

Trial Locations (6)

15706

Hospital Clínico Universitario de Santiago, Santiago de Compostela

20014

Hospital Universitario Donostia, Donostia / San Sebastian

29010

Hospital Universitario Virgen De La Victoria, Málaga

39008

Hospital Universitario Marqués del Valdecilla, Santander

50009

Hospital Universitario Miguel Servet, Zaragoza

08035

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors

Collaborators (1)

Agenus Inc.
All Listed Sponsors
collaborator

Apices Soluciones S.L.

INDUSTRY

collaborator

Agenus Inc.

INDUSTRY

lead

Nelum Corp

INDUSTRY

NCT04827953 - Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter